Back to all announcements

DJ Sativa Group PLC DHSC & Home Office CBMP import relaxation welcomed


RNS Number : 8726E

Sativa Group PLC

03 March 2020

 Press Release   3(rd) March 2020 

Sativa Group Plc

("Sativa" or "the Company" or "the Group")

Comment on faster access for patients to cannabis-based medicinal products (CBMPs) following relaxation of import restrictions by

the Department of Health and Social Care (DHSC) and the Home Office

Yesterday the Department of Health and Social Care (DHSC) and the Home Office announced that patients will be able to get faster access to cannabis-based medicinal products (CBMPs) through the relaxation of import restrictions. Sativa welcomes this initiative as it endorses the Group's view that the UK is fast-developing as a significant medicinal cannabis market in which it intends to extend its participation and maintain its position as the UK's leading quoted CBD wellness and medicinal cannabis Group.

Sativa Chief Executive Henry Lees-Buckley said: "Yesterday's announcement by Matt Hancock, the Secretary of State for Health and Social Care, goes some way towards levelling the playing field and making cannabis-based remedies more affordable and accessible to all.

"However, there is still a long way to go to bring the UK in parallel with other countries where the benefits of cannabis-based remedies have been accessible for many years and the UK's own medicinal cannabis industry remains very much fettered."

Sativa is fortunate in holding one of the few Home Office Controlled Drug licences that allows it to cultivate, produce and supply cannabis for research purposes. It allows the Group to fulfil its agreement with King's College London to supply the College with material as it researches the impact of cannabinoids on inflammation and respiratory diseases. That runs in parallel with the Group's highly successful Goodbody CBD Wellness retail business and PhytoVista Laboratory service.

   -     Ends - 

Media enquiries.

 Abchurch Communications 
  Julian Bosdet    
  +44 (0)207 4594 4070 
  +44 (0) 7771 663 886 

For further information please contact:

 Henry Lees-Buckley               Joseph Colliver 
  Chief Executive Officer          Chief Financial Officer 
  Sativa Group Plc                 Sativa Group Plc 
  +44 (0) 20 7971 1255             +44 (0) 20 7971 1255   
 NEX Exchange Corporate Adviser 
  Corporate Finance                 Equity Sales 
  Stephen Keys / Max Gould          Julian Morse 
  Cenkos Securities plc             Cenkos Securities 
  +44 (0) 20 7397 8900              +44 (0) 20 7397 8900 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

March 03, 2020 08:14 ET (13:14 GMT)